| 摘要 |
Reagents which regulate human phosphodiesterase-like enzyme (PDE-like enzyme) activity and reagents which bind to human PDE-like enzyme gene products can be used to regulate degradation of cGMP. Such regulation is particularly useful for treating urinary incontinence, benign prostate hyperplasia, erectile dysfunction, diabetes, cancer, and cardiovascular disorders. |
